MMMargherita Melegari

Margherita Melegari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Margherita Melegari has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Thioredoxin Reductase 1 inhibition triggers ferroptosis in KRAS-independent lung cancers

    by Cristina Andreani, Caterina Bartolacci, Margherita Melegari, Nicola Sargentoni, Lorenzo Luciani, Agnese Marucci, Roberta Galeazzi, Gina M. DeNicola, Jessica Kilgore, Noelle Williams, et al.

    Lung cancers that harbor wild type KRAS (KRAS-WT) represent a molecularly diverse subset of tumors that often lack targeted therapeutic options. Using synthesized gold(I)-based inhibitors, a multi-omics approach, and functional validation, we identified Thioredoxin reductase 1 (TXNRD1), encoding as a selective vulnerability in KRAS-WT and oncogenic KRAS mutant (KM)-independent lung cancer (LC). Mechanistically, TRXR1 blockade induces ferroptosis through glutathione depletion, lipid reactive oxygen species (ROS) accumulation, and HMOX1-dependent iron overload in KRAS-WT LC both in vitro and in vivo. Furthermore, while KM LC cells are intrinsically resistant to TRXR1 inhibition, KMLC cells that acquire resistance to KRAS inhibitors (KRASi) undergo a redox shift that renders them sensitive to TRXR1 inhibition, uncovering a potential novel therapeutic vulnerability in KRASi-refractory tumors. These findings establish TRXR1 as a targetable redox checkpoint in KRAS-WT and KRASi-resistant lung cancers and support further development of TRXR1 inhibitors.


  • Open Access

    PIAS1-FAK Interaction Promotes the Survival and Progression of Non-Small Cell Lung Cancer

    by Jerfiz D. Constanzo, Ke-Jing Tang, Smita Rindhe, Margherita Melegari, Hui Liu, Ximing Tang, Jaime Rodriguez-Canales, Ignacio Wistuba, Pier Paolo Scaglioni


  • Nucleic acid‐based antiviral and gene therapy of chronic hepatitis B infection

    by Jr Wands, M Geissler, Jzu Putlitz, H Blum, F VON Weizsäcker, L Mohr, Sk Yoon, M Melegari, Pp Scaglioni

    Persistent hepatitis B virus (HBV) infection often leads to the development of chronic hepatitis, cirrhosis and hepatocellular carcinoma. There is a need to develop new antiviral approaches for the treatment of this disease. We have explored various nucleic acid-based strategies designed to inhibit HBV replication including: the use of antisense RNA and DNA constructs, DNA-based immunization techniques to stimulate broad-based cellular immune responses with particular emphasis on the generation of cytotoxic lymphocyte (CTL) activity to viral structural proteins, hammerhead ribozymes to cleave HBV pregenomic RNA in vitro and dominant negative HBV core mutant proteins as inhibitors of nucleocapsid formation within cells. In order to optimize these antiviral effects, various novel expression vectors have been developed to deliver such DNA constructs to cells. For example, adenoviral vectors carrying genes that encode for dominant negative proteins have been employed to transfect hepatocytes in vitro and in vivo. In addition, plasmid vectors have been produced to promote expression of HBV structural genes following injection into muscle cells as a means to stimulate the host's cellular and humoral immune response in the context of histocompatibility antigen (HLA) class I and II antigen presentation. These experimental approaches may have important implications for the generation of efficient antiviral effects during chronic HBV infection.


  • Conserved core protein sequences in hepatitis B virus infected patients without anti-HBc

    by Margherita Melegari, Maria-Christina Jung, Ralf Schneider, Teresa Santantonio, Serenella Bagnulo, Nicoletta Luchena, Giuseppe Pastore, Gerd Pape, Pier Paolo Scaglioni, Erica Villa, et al.